All articles by

Kyverna Therapeutics begins participants enrolment in Phase I KYV-101 trial

The Phase I clinical trial is expected to enrol approximately nine to 12 LN patients across the US.

Aldeyra reports positive top-line data from Phase II trial of ADX-2191

Findings from the trial showed that the treatment with ADX-2191 significantly improved retinal function.

LianBio concludes subject enrolment in Phase III TP-03 trial in China

Mite eradication and complete collarette cure are the co-primary endpoints of the trial.

Azafaros begins subject enrolment in Phase II RAINBOW trial of AZ-3102

The trial will assess the pharmacokinetics, pharmacodynamics, tolerability, and safety of AZ-3102 across two doses.

AstraZeneca reports positive data from lung cancer combo therapy trial

The Tagrisso and chemotherapy combination therapy showed strong improvement in progression-free survival.

MindMed completes 50% subject enrolment and dosing in GAD therapy trial

The trial will assess four MM-120 doses to treat anxiety symptoms in GAD diagnosed patients.

Indapta plans Phase I trial of NK Cell therapy

The trial will assess three different dose levels of G-NK cells alone and along with interleukin-2 and the monoclonal antibodies.

Phio Pharmaceuticals receives FDA IND clearance for PH-762 trial

The first Phase Ib trial will assess the tolerability and safety of neoadjuvant use of intratumorally injected PH-762.

Protara begins subject dosing in Phase Ib ADVANCED-1EXP expansion trial

The trial will assess the intravesical TARA-002 at the 40KE dose in 12 patients with CIS.

KinoPharma, IWAKI SEIYAKU start Phase II study of cutaneous warts drug

The trial will confirm the efficacy of the drug candidate for the treatment of cutaneous warts.